Also known as A-7 pancreas peptide · pancreatic peptide complex
A natural pancreas peptide complex (Cytomax A-7) — the extract-based counterpart to Pancragen, targeting pancreatic tissue.
Research refreshed
Suprefort is a natural peptide complex extracted from pancreatic tissue (peptide complex A-7), part of the Russian Cytomax / Revilab bioregulator line. It is the extract-based pancreatic counterpart to the synthetic peptide Pancragen, marketed within the Khavinson tradition for carbohydrate-metabolism and pancreatic support.
Suprefort is the pancreas-directed natural bioregulator of the Cytomax / Revilab line. It pairs with Pancragen, the synthetic pancreatic short peptide already catalogued: Suprefort is the natural pancreatic extract, Pancragen the defined synthetic peptide modeled on the same tissue.
As a tissue extract it is a standardized polypeptide fraction with no single molecular formula or sequence. Its metabolic claims — supporting carbohydrate metabolism and pancreatic function — come from the same concentrated research tradition as the rest of the series, with limited independent replication, and it is not FDA-approved.
Proposed tissue-selective (bioregulator) modulation of pancreatic gene expression, in the same lineage as the synthetic pancreas peptide Pancragen.
Behind every vial of Suprefort is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Suprefort, specifically, is brought into being.
Suprefort begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Suprefort is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Suprefort plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Suprefort proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Suprefort — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Suprefort is a natural pancreas peptide extract (complex A-7), a fractionated polypeptide preparation rather than a synthesized peptide. Batch-to-batch consistency and characterization, not coupling chemistry, are the quality challenge.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Suprefort is a natural pancreas peptide complex (Cytomax A-7), marketed for metabolic and pancreatic support — the extract-based counterpart to the synthetic peptide Pancragen.
Suprefort is the natural pancreatic extract; Pancragen is the defined synthetic peptide modeled on the same tissue.
No — it is a tissue extract (a polypeptide fraction), so it has no single sequence or molecular formula.
No — it is a research compound / supplement, not FDA-approved. This page is a research and educational reference.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.